Lloyd Richard Mitchell

US Patent:

6673621, Jan 6, 2004

Filed:

Jun 9, 1999

Appl. No.:

09/147698

Inventors:

Lloyd G. Mitchell - Durham NC

Assignee:

Intronn LLC - Durham NC

International Classification:

G01N 3700

US Classification:

436 56, 435 6, 422102, 436 94

Abstract:

The invention is directed to a device suitable for marking a collected sample, comprising collecting means for collecting the sample and at least one detectable marker which is associated with at least a portion of the collecting means, wherein the at least one detectable marker is contractable with the sample upon collection of the sample to mark the collected sample upon contact of the sample with the at least a portion of the collecting means having the at least one detectable marker associated therewith, and wherein the at least one detectable marker is other than a component which is present in the sample before collection and is inert to any component present in the sample before collection. Kits containing the device, methods for marking samples using the device, methods for determining the integrity of a marked sample, and use of the markers for the testing of laboratories and/or laboratory personnel for certification, proficiency testing or accreditation purposes are also provided.

US Patent:

7901892, Mar 8, 2011

Filed:

Jul 8, 2002

Appl. No.:

10/190795

Inventors:

Paul F. Agris - Raleigh NC, US
Christopher D. J. Pearce - Surrey, GB
Lloyd G. Mitchell - Durham NC, US

Assignee:

North Carolina State University - Raleigh NC

International Classification:

G01N 33/53

US Classification:

435 71, 435 6

Abstract:

This application describes an antibody that specifically binds to a synthetic oligomer (e. g. , an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.

US Patent:

8173377, May 8, 2012

Filed:

Jan 28, 2011

Appl. No.:

13/016409

Inventors:

Paul F. Agris - Raleigh NC, US
Christopher D. J. Pearce - Surrey, GB
Lloyd G. Mitchell - Durham NC, US

Assignee:

North Carolina State University - Raleigh NC

International Classification:

G01N 33/53

US Classification:

435 71, 435 72, 435518

Abstract:

This application describes an antibody that specifically binds to a synthetic oligomer (e. g. , an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.

US Patent:

8323910, Dec 4, 2012

Filed:

Apr 5, 2012

Appl. No.:

13/440613

Inventors:

Paul F. Agris - Raleigh NC, US
Christopher D. J. Pearce - Surrey, GB
Lloyd G. Mitchell - Durham NC, US

Assignee:

North Carolina State University - Raleigh NC

International Classification:

G01N 33/53

US Classification:

435 71, 436518

Abstract:

This application describes an antibody that specifically binds to a synthetic oligomer (e. g. , an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.

US Patent:

20020115207, Aug 22, 2002

Filed:

Jan 8, 2001

Appl. No.:

09/756095

Inventors:

Lloyd Mitchell - Durham NC, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Durham NC, US
S. Mansfield - Durham NC, US

International Classification:

C12P021/02
C12N005/06
C07H021/04

US Classification:

435/325000, 435/320100, 536/023100

Abstract:

The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

US Patent:

20030027250, Feb 6, 2003

Filed:

Aug 29, 2001

Appl. No.:

09/941492

Inventors:

Lloyd Mitchell - Durham NC, US
Mariano Garcia-Blanco - Durham NC, US
Carl Baker - Potomac MD, US
Madaiah Puttaraju - Durham NC, US

International Classification:

C12P021/02
C12N005/06
C12N015/86

US Classification:

435/069100, 435/325000, 435/456000

Abstract:

The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

US Patent:

20030077754, Apr 24, 2003

Filed:

Jan 8, 2001

Appl. No.:

09/756096

Inventors:

Lloyd Mitchell - Durham NC, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Durham NC, US
S. Mansfield - Durham NC, US

International Classification:

C12N009/00
C07H021/04
C12P021/04
C12N005/06

US Classification:

435/069700, 435/320100, 435/325000, 536/023200, 435/183000

Abstract:

The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

US Patent:

20030148937, Aug 7, 2003

Filed:

Apr 20, 2001

Appl. No.:

09/838858

Inventors:

S. Mansfield - Durham NC, US
Lloyd Mitchell - Durham NC, US
Mariano Garcia-Blanco - Durham NC, US
Christopher Walsh - Chapel Hill NC, US
Hengjun Chao - Carboro NC, US

International Classification:

A61K038/37
C12Q001/68
C12N005/06
C07K014/755

US Classification:

514/012000, 435/325000, 435/006000, 530/383000

Abstract:

The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.